Perceptive Advisors LLC has recently announced that it has increased stake in Amicus Therapeutics Inc (NASDAQ:FOLD) by 0.11%. After grabbing 27.69 million shares, the institutional investor is now in possession of 30000.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 9.44% having worth around $305.18 million. Moreover, The Vanguard Group, Inc. increased its share by 0.1 million to have a control over 26.38 million shares. And Janus Henderson Investors US LLC raised its holdings to 6929.0 shares by acquiring 14.82 million shares or 5.05% of the stake.
Amicus Therapeutics Inc (FOLD) concluded trading on 01/04/24 at a closing price of $13.44, with 2.86 million shares of worth about $38.47 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 11.07% during that period and on Thursday the price saw a loss of about -0.67%. Currently the company’s common shares owned by public are about 293.25M shares, out of which, 284.37M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 11 analysts are covering the FOLD stock and their offered price forecasts bring an average price target of $19.33. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $21.00 and could fall to a lowest price of $15.00. The stock’s current price level is 30.47% above of average price target set by the analysts, while a rise to estimated low would result in gain of 10.4% for the stock. However, touching the estimated high of $21.00 would mean a gain of 36.0% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 92 times over the past 12 months. They bought 1,052,804 shares in 36 of the transactions. In 56 selling transactions, insiders dumped 918,402 shares.
Vanguard Total Stock Market ETF, Vanguard Small Cap Index Fund, and Janus Henderson Contrarian Fund are the top 3 mutual funds which are holding stakes in Amicus Therapeutics Inc Vanguard Total Stock Market ETF is currently holding 9.01 million shares of worth totaling $99.24 million. The company recently came buying 16210.0 shares which brought its stake up to 3.07% of the company’s outstanding shares. Vanguard Small Cap Index Fund bought 22776.0 shares, after which its hold over company’s outstanding shares expand to 2.54%, leaving 7.43 million shares with the mutual fund that have a worth of about $81.91 million. Janus Henderson Contrarian Fund, after buying 7.25 million shares, have now control over 2.47% of the stake in the company. It holds 0.0 shares of worth $79.84 million.
Amicus Therapeutics Inc (NASDAQ: FOLD) started trading at $13.60, above $0.07 from concluding price of the previous day. However, the stock later moved at a day high price of 13.60, or with a loss of -0.67%. Stock saw a price change of -6.86% in past 5 days and over the past one month there was a price change of 21.08%. Year-to-date (YTD), FOLD shares are showing a performance of -5.29% which increased to 12.66% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $9.70 but also hit the highest price of $14.57 during that period. The average intraday trading volume for Amicus Therapeutics Inc shares is 2.88 million. The stock is currently trading 4.99% above its 20-day simple moving average (SMA20), while that difference is up 15.52% for SMA50 and it goes to 11.85% higher than SMA200.
Perceptive Advisors LLC acquired 27.69 million shares of Amicus Therapeutics Inc having value of about $305.18 million. Data submitted at the U.S SEC by Perceptive Advisors LLC revealed that the firm now holds 30000.0 shares in the company valued at close to $403200.0, or have control over 0.11% stake in the company. Amicus Therapeutics Inc (NASDAQ: FOLD) currently have 293.25M outstanding shares and institutions hold larger chunk of about 102.42% of that. Holding of mutual funds in the company is about 47.64% while other institutional holders and individual stake holders have control over 54.87% and 23.03% of the stake respectively.
The stock has a current market capitalization of $3.94B and its 3Y-monthly beta is at 0.78. It has posted earnings per share of -$0.60 in the same period. It has Quick Ratio of 2.40 while making debt-to-equity ratio of 3.41. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for FOLD, volatility over the week remained 3.63% while standing at 3.68% over the month.
Analysts are in expectations that Amicus Therapeutics Inc (FOLD) stock would likely to be making an EPS of $ProShares UltraShort Bloomberg in the current quarter, while forecast for next quarter EPS is $77.23 and it is $ETF for next year. For the current quarter EPS, analysts have given the company a lowest target $Forward Industries, Inc. which is $Amicus Therapeutics, Inc. at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $Americold Realty Trust, Inc. in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 44.03% while it is estimated to increase by 123.37% in next year.
Analysts at 11 brokerage firms have issued recommendations for the Amicus Therapeutics Inc (FOLD)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.55. Out of those 11 Wall Street analysts, 8 recommended a “Buy” rating, while 3 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Morgan Stanley on December 19, 2023 offering an Overweight rating for the stock and assigned a target price range of between $15 and $20 to it.
